Next Article in Journal
Peptide Inhibitors of Vascular Endothelial Growth Factor A: Current Situation and Perspectives
Next Article in Special Issue
Mesenchymal Stromal Cells: Potential Option for COVID-19 Treatment
Previous Article in Journal
Gene Expression and Protein Abundance of Hepatic Drug Metabolizing Enzymes in Liver Pathology
Previous Article in Special Issue
Mesenchymal Stromal Cells Perspective: New Potential Therapeutic for the Treatment of Neurological Diseases
Review

Wharton’s Jelly Mesenchymal Stromal Cells and Derived Extracellular Vesicles as Post-Myocardial Infarction Therapeutic Toolkit: An Experienced View

by 1,†, 2,3,4,5,†, 2,3,4,6,* and 1,7,8,*
1
Servei de Teràpia Cel·lular, Banc de Sang i Teixits, Edifici Dr. Frederic Duran i Jordà, Passeig Taulat, 116, 08005 Barcelona, Spain
2
ICREC Research Program, Germans Trias i Pujol Health Science Research Institute, Can Ruti Campus, 08916 Badalona, Spain
3
Heart Institute (iCor), Germans Trias i Pujol University Hospital, Carretera de Canyet s/n, 08916 Badalona, Spain
4
CIBER Cardiovascular, Instituto de Salud Carlos III, 28029 Madrid, Spain
5
Faculty of Medicine, University of Vic-Central University of Catalonia, 08500 Vic, Spain
6
Institut d’Investigació Biomèdica de Bellvitge—IDIBELL, 08907 L’Hospitalet de Llobregat, Spain
7
Musculoskeletal Tissue Engineering Group, Vall d’Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Passeig de la Vall d’Hebron 129-139, 08035 Barcelona, Spain
8
Departament de Medicina, Universitat Autònoma de Barcelona, Passeig de la Vall d’Hebron 129-139, 08035 Barcelona, Spain
*
Authors to whom correspondence should be addressed.
The first two authors (N.M.-D. and S.R.) contributed equally to this work.
Academic Editors: Edorta Santos-Vizcaino and Eun Seong Lee
Pharmaceutics 2021, 13(9), 1336; https://doi.org/10.3390/pharmaceutics13091336
Received: 9 July 2021 / Revised: 18 August 2021 / Accepted: 23 August 2021 / Published: 26 August 2021
Outstanding progress has been achieved in developing therapeutic options for reasonably alleviating symptoms and prolonging the lifespan of patients suffering from myocardial infarction (MI). Current treatments, however, only partially address the functional recovery of post-infarcted myocardium, which is in fact the major goal for effective primary care. In this context, we largely investigated novel cell and TE tissue engineering therapeutic approaches for cardiac repair, particularly using multipotent mesenchymal stromal cells (MSC) and natural extracellular matrices, from pre-clinical studies to clinical application. A further step in this field is offered by MSC-derived extracellular vesicles (EV), which are naturally released nanosized lipid bilayer-delimited particles with a key role in cell-to-cell communication. Herein, in this review, we further describe and discuss the rationale, outcomes and challenges of our evidence-based therapy approaches using Wharton’s jelly MSC and derived EV in post-MI management. View Full-Text
Keywords: biomanufacturing; cardiac tissue engineering; clinical translation; extracellular vesicles; mesenchymal stromal cells; myocardial infarction; Wharton’s jelly biomanufacturing; cardiac tissue engineering; clinical translation; extracellular vesicles; mesenchymal stromal cells; myocardial infarction; Wharton’s jelly
Show Figures

Figure 1

MDPI and ACS Style

Muñoz-Domínguez, N.; Roura, S.; Prat-Vidal, C.; Vives, J. Wharton’s Jelly Mesenchymal Stromal Cells and Derived Extracellular Vesicles as Post-Myocardial Infarction Therapeutic Toolkit: An Experienced View. Pharmaceutics 2021, 13, 1336. https://doi.org/10.3390/pharmaceutics13091336

AMA Style

Muñoz-Domínguez N, Roura S, Prat-Vidal C, Vives J. Wharton’s Jelly Mesenchymal Stromal Cells and Derived Extracellular Vesicles as Post-Myocardial Infarction Therapeutic Toolkit: An Experienced View. Pharmaceutics. 2021; 13(9):1336. https://doi.org/10.3390/pharmaceutics13091336

Chicago/Turabian Style

Muñoz-Domínguez, Noelia, Santiago Roura, Cristina Prat-Vidal, and Joaquim Vives. 2021. "Wharton’s Jelly Mesenchymal Stromal Cells and Derived Extracellular Vesicles as Post-Myocardial Infarction Therapeutic Toolkit: An Experienced View" Pharmaceutics 13, no. 9: 1336. https://doi.org/10.3390/pharmaceutics13091336

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop